Document is current
Any future updates will be listed below
-
Authors
Scoville, Elizabeth A.
Allaman, Margaret M.
Adams, Dawn W.
Motley, Amy K.
Peyton, Shannon C.
Ferguson, Sarah L.
Horst, Sara N.
Williams, Christopher S.
Beaulieu, Dawn B.
Schwartz, David A.
Wilson, Keith T. https://orcid.org/0000-0003-4421-1830
Coburn, Lori A.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK099204, P30DK058404, 5T32DK007673)
U.S. Department of Veterans Affairs (I01BX001426, I01BX001453, 1IK2BX002126)
U.S. Department of Health & Human Services | National Institutes of Health (R01AT004821, 3R01AT004821-02S1, R01DK053620, R01CA190612, P01CA028842, P01CA116087, UL1TR000445, DK20593)
- License Information
-
More Information
Article History
Received: 12 October 2018
Accepted: 18 January 2019
First Online: 27 February 2019
Competing Interests
: David A. Schwartz has consultancy agreements with Abbvie, UCB, Janssen, Takeda, Tigenix, Genentech, and Gilead. Dawn B. Beaulieu has a consultancy agreement with Abbvie. Sara N. Horst has consultancy agreements with UCB, Janssen, and Salix. However, these agreements and grants had no relationship to the current research study. Keith T. Wilson has had a consulting agreement with Immune Pharmaceuticals. However, this agreement had no relationship to the current research study and is no longer active. The remainder of the authors declare that they have no financial or non-financial conflicts of interest.
